Clinical evaluation of huperzine A in improving interlligent disorder in patients with Alzheimer's disease

Chinese Journal of Clinical Rehabilitation

Volumn 8, Issue 7, 2004, Pages 1216-1217

  Kuang, Ming Zi ^a   Xiao, Wei Min ^a   Wang, Shi Fang ^a   Li, Run Xiong ^a  

^a DONGGUAN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUPERZINE A; PIRACETAM;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BRAIN ATROPHY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX RATIO;

EID: 2442566571     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Alessandro B, Roberto F, Maria EB, et al. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. Am J Neuroradiol 2001; 22: 1030-6
2. Nitrini R, Buchpiguel CA, Caramelli P, et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurol Scand 2000; 101: 172-6
3. Eustache F, Desgranges B, Giffard B, et al. Entorhimal cortex disruption causes memory deficit in early Alzheimer's disease as shown by PET. Neuroreport 2001; 12: 693-5
4. Fama R, Sullivan EV, Shear PK, et al. Selective cortical and hippocampal volume correlates of matlis dementia vating scale in Alzheimer disease. Arch Neurol 1997;54:719
5. Chinese source. 2003, 7(5): 785-6
6. Hunter AJ, Murray TK, Jone JA, et al. The cholinergic phamacology of tetrahydroam inoacridine in vivo and in vitro. Br J Pharmacol 1989; 98: 79-86
7. Chinese source. 2003, 7(16): 2350-1
8. Chinese source. 2003, 7(10): 1538-9
9. Chinese source. 2000, 13(8): 462-3